While S100A9, its binding partner S100A8 and its receptor TLR4 were all significantly upregulated in AML patient compared to normal bone marrow sample, we observed no prognostic value for these genes in AML patients (Fig. 1C–F, Supplemental Fig. 1). The gene discussed is S100A8; the disease is acute myeloid leukemia.